Does Medicaid Cover Weight Loss Drugs? State Rules and Approval

Whether Medicaid covers weight loss drugs depends on your state and on why the drug is being prescribed. For type 2 diabetes, cardiovascular disease, or sleep apnea, GLP-1 medications like Ozempic, Wegovy, and Zepbound are covered by Medicaid in every state. For obesity alone, only 13 state Medicaid programs covered these drugs as of January 2026, and that number has been falling.¹

Why the Answer Depends on Your State

Federal law lets states opt out. Section 1927(d)(2) of the Social Security Act generally requires Medicaid to cover FDA-approved drugs, but it carves out an exception for medications used for “anorexia, weight loss, or weight gain.” Each state decides whether to use that exclusion.¹ The language was written decades ago, when weight loss drugs were viewed more as cosmetic aids than treatments for a chronic disease, and it remains the law today.

The result is a patchwork. A Wisconsin Medicaid enrollee can get Wegovy or Zepbound covered for obesity (with prior authorization and strict clinical criteria). Someone with the same diagnosis in a non-covering state has no such benefit.¹

One important carve-out: enrollees under 21. Federal law requires Medicaid to provide all medically necessary treatments to this age group through the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, so states cannot categorically deny GLP-1s for weight loss to minors the way they can for adults. Pennsylvania, for example, ended adult coverage of GLP-1s for obesity in January 2026 but kept covering them for enrollees under 21 under EPSDT.²

Which States Cover Weight Loss Drugs, and Which Have Dropped Them

The trend has moved toward less coverage, not more. In October 2025, 16 state Medicaid programs covered GLP-1s for obesity. By January 2026, that number was down to 13 after California, New Hampshire, Pennsylvania, and South Carolina all eliminated the benefit.¹ More states are considering similar changes.

Cost is the common reason. Pennsylvania, which had covered GLP-1s for obesity since 2023, reported spending $650 million on these drugs across all indications in 2024 and projected costs would exceed $1 billion annually without restrictions.³ The state ended coverage for adult weight loss effective January 1, 2026, but continued covering GLP-1s for diabetes, cardiovascular risk reduction, sleep apnea, and liver disease.⁴

North Carolina shows how volatile these decisions can be. The state eliminated GLP-1 coverage for obesity in October 2025 citing funding shortfalls, then reinstated it in December 2025 after a budget deal.⁵¹

Michigan took a middle path. Rather than ending coverage entirely, the state restricted GLP-1 eligibility to patients with morbid obesity (BMI of 40 or above) effective January 1, 2026. Enrollees must have tried and failed other weight loss interventions, including preferred drugs like phentermine and Qsymia, and a physician must attest that a GLP-1 is necessary to avoid bariatric surgery. The restriction is expected to save $240 million in 2026, but up to one million Medicaid enrollees who are overweight or obese could lose access.⁶⁷

Two more are already on the schedule. Massachusetts announced it will end MassHealth coverage for GLP-1s used solely for weight loss effective July 1, 2026, a change affecting at least 22,000 enrollees.⁸ Rhode Island’s governor proposed removing coverage in the state’s fiscal year 2027 budget, with no grandfathering for existing patients if enacted.⁹

Because the list is changing, the practical first step is to check your state Medicaid agency’s current preferred drug list or call member services. A plan that covered Wegovy last year may not cover it this year.

What You Have to Prove to Get a Prescription Approved

In states that do cover GLP-1s for obesity, getting a prescription filled through Medicaid is rarely as simple as a doctor writing one. Prior authorization is the norm, and the criteria can be extensive. Wisconsin’s program is a representative example of what states typically require:

A BMI of 30 or above, or a BMI between 27 and 30 with at least two risk factors such as hypertension, type 2 diabetes, dyslipidemia, or a cardiovascular disease history.
Participation in a weight loss treatment plan (nutritional counseling, exercise, calorie-restricted diet) for six months before the authorization request, continuing during drug therapy.
After an initial approval period of about six months, documented weight loss of at least 5% of baseline body weight to renew coverage of drugs like Wegovy and Zepbound.
Only two weight loss attempts per drug group in a member’s lifetime, with continuous GLP-1 therapy capped at 12 months.
Ineligibility for patients who are pregnant, nursing, or have a history of eating disorders or substance abuse.

Coverage is limited to one anti-obesity medication at a time, and authorization lapses if a patient’s BMI drops below 24.¹⁰

Michigan’s newer policy goes further by requiring documented failure of cheaper preferred drugs (phentermine and Qsymia) before a GLP-1 can be authorized, and limits eligibility to patients with a BMI of 40 or higher.¹¹ The specific criteria vary by state, so your prescriber will need to document eligibility according to your plan’s rules.

Older Weight Loss Drugs That Medicaid May Still Cover

Even in states that exclude GLP-1s for weight loss, some older and less expensive anti-obesity medications may still be available. Phentermine, diethylpropion, phendimetrazine, and orlistat have been on the market for decades and cost a fraction of what GLP-1s cost. North Carolina continued covering these “non-incretin mimetics” on its preferred drug list without prior authorization after it had briefly discontinued GLP-1 coverage for obesity.⁵ Pennsylvania similarly kept phentermine capsules and tablets available as preferred drugs for obesity after cutting GLP-1 access.⁴

These older drugs are generally less effective than GLP-1s for weight loss and come with their own limits on treatment duration and patient eligibility. But if your state excludes GLP-1s, they may be the only pharmacological option Medicaid will pay for.

Pricing Deals That Could Change State Decisions

The federal government has not required Medicaid to cover GLP-1s for obesity, but it has tried to lower what the drugs cost. In December 2025, CMS announced the BALANCE Model, a voluntary program that lets the agency negotiate lower GLP-1 prices with manufacturers on behalf of participating state Medicaid agencies and Medicare Part D plans.¹²

State participation began on a rolling basis starting May 1, 2026, with applications due by July 31, 2026. States that join get a confidential negotiated price and must adopt standardized coverage criteria that tie eligibility to BMI and comorbidities:

BMI of 35 or above, with provider attestation of lifestyle modification and a qualifying comorbidity such as type 2 diabetes, liver disease, or sleep apnea.
BMI of 30 or above, with heart failure, uncontrolled hypertension, chronic kidney disease (stage 3a or higher), moderate-to-severe sleep apnea, or advanced liver fibrosis.
BMI of 27 or above, with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

States can set broader criteria than the model’s baseline but cannot set more restrictive ones. Manufacturers must also provide free lifestyle support programs covering diet, physical activity, and medication adherence to enrollees receiving the drugs.¹³

Separately, the administration reached agreements with Novo Nordisk and Eli Lilly to lower GLP-1 prices across government programs. Medicare beneficiaries pay $50 per month for drugs like Wegovy and Zepbound (at a net price of $245 per 30-day supply), and state Medicaid programs are guaranteed access to “Most-Favored-Nation” pricing.¹⁴ Because Medicaid enrollees already pay little to nothing out of pocket, these deals primarily affect state budgets, not what patients see at the pharmacy.¹ Whether the lower prices will be enough to bring states back to covering GLP-1s for obesity depends on how many states sign on and how the numbers work in each state budget.¹⁵

1
KFF. Medicaid Coverage of and Spending on GLP-1s
2
Pennsylvania Health Law Project. PA Medicaid Ends Adult Coverage of GLP-1s for Weight Loss
3
WHYY. Health Care Laws in Pennsylvania, New Jersey, Delaware
4
Commonwealth of Pennsylvania. Medical Assistance Bulletin Regarding GLP-1 Coverage Changes
5
NC Department of Health and Human Services. NC Medicaid Change in Coverage for GLP-1 Weight Management Medications
6
U.S. News & World Report. Michigan to Limit Medicaid Coverage for Weight Loss Drugs
7
University of Michigan Medicine Research. Michigan Medicaid’s New Limits on GLP-1 Weight Management Medications
8
WBUR. Mass. Cutting GLP-1 Coverage for Medicaid Weight Loss
9
Rhode Island Current. McKee’s Proposed FY2027 Budget Drops GLP-1 Drugs for Weight Loss From Medicaid
10
Wisconsin ForwardHealth. Anti-Obesity Drugs Prior Authorization Criteria
11
Michigan DHHS. Numbered Letter L-25-73 Pharmacy
12
CMS. BALANCE Model
13
CMS. BALANCE State Medicaid Request for Applications
14
The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients
15
KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid